Our product candidate, AN0128, combines antibiotic properties with significant anti-inflammatory activity. We believe that this combination of antibiotic and anti-inflammatory properties gives AN0128 the potential to treat a number of indications, including gingivitis and acne.

AN0128's anti-inflammatory properties are a result of inhibition of pro-inflammatory cytokines, including TNF-alpha. In preclinical studies AN0128 has demonstrated antimicrobial activity against bacteria involved in gingivitis and shown effectiveness against bacteria in biofilms, which are generally difficult to treat. In addition, AN0128 reduced gingival inflammation in animal studies. AN0128 has also demonstrated activity in in vitro studies against antibiotic resistant strains of bacteria and other bacteria commonly found in the skin, and demonstrated inflammation-reducing activity similar to corticosteroids in animal models of inflammation.